Aqualung Therapeutics Receives FDA Clearance To Proceed With the P2A PUERTA Study in Moderate/Severe Acute Respiratory Distress Syndrome (ARDS) Patients
Aqualung Therapeutics will initiate moderate/severe ARDS patient recruitment for U.S. and Australia hospital sites in August 2023.Aqualung appoints Jackson Streeter MD to their board of...